As shown in Figure 2A–D, in low dose PAOS or glibenclamide treatment group, the levels of IL-1β (p = 0.0021, p = 0.003) were lower, and the level of IL-10 (p = 0.0056, p = 0.014) were higher in DM group. Here, IL10 is linked to diabetes mellitus.